{"doi":"10.1007/978-3-030-73440-4_4","title":"Mechanisms Driving Resistance to Proteasome Inhibitors Bortezomib, Carfilzomib, and Ixazomib in Multiple Myeloma","abstract":null,"journal":"Resistance to Targeted Anti-Cancer Therapeutics","year":2021,"id":24147,"datarank":0.12407021435295747,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"self_citation_contribution":0.10397207708399181,"citation_network_contribution":0.02009813726896566,"self_endowment_contribution":0.10397207708399181,"citer_contribution":0.02009813726896566,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":1,"citers_with_citation_signal":1,"citers_with_endowment":1,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":145815,"name":"Stuart M. Pitson","orcid":null,"position":1,"is_corresponding":false},{"id":145816,"name":"Craig T. Wallington-Beddoe","orcid":null,"position":2,"is_corresponding":false},{"id":145814,"name":"Melissa K. Bennett","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"18998881","pmcid":null,"openalex_id":"https://openalex.org/W3184357652","authors":[],"funders":[],"total_grants":0,"fwci":1.4653,"citation_percentile":0.82721713,"influential_citations":0,"citation_trend":[{"year":2022,"count":1}],"oa_status":"closed","license":"https://www.springer.com/tdm","oa_locations":[{"url":"https://link.springer.com/content/pdf/10.1007/978-3-030-73440-4_4","host_type":"publisher"},{"url":"https://doi.org/10.1007/978-3-030-73440-4_4","host_type":"book series"}],"fields_of_study":["Multiple Myeloma Research and Treatments","Protein Degradation and Inhibitors","Ubiquitin and proteasome pathways","Medicine"],"mesh_terms":[],"keywords":["Carfilzomib","Ixazomib","Bortezomib","Multiple myeloma","Proteasome inhibitor","Proteasome","Pharmacology","Medicine","Cancer research","Internal medicine","Biology","Genetics"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-07T21:39:35.835973Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}